PQA Convenes: Quality Medication Use in Rare Disease: A Report on Stakeholder Perspectives on What Constitutes Quality
Health care organizations today approach rare disease quality medication use in a variety of ways, and there are many perspectives on what constitutes quality and how to improve it. A need and opportunity exists to establish a consensus on what constitutes high-quality rare disease medication use. To advance the national conversation, PQA hosted a one-day event on November 7, 2024, to discuss stakeholder perspectives on rare disease medication use quality.
The event, PQA Convenes: Quality Medication Use in Rare Disease, provided a platform for four key stakeholders in the medication use process to share their perspective on what constitutes quality:
- Patients, caregivers and patient advocates
- Specialty pharmacies and providers
- Biopharmaceutical industry organizations
- Public and private payers
PQA Convenes: Quality Medication Use in Rare Disease: A Report on Stakeholder Perspectives on What Constitutes Quality summarizes the perspectives shared over a series of four discussion panels featuring 20 speakers and moderators.
Download the Report